QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:NGM

NGM Biopharmaceuticals - NGM Stock Forecast, Price & News

$5.53
-0.07 (-1.25%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.42
▼
$5.71
50-Day Range
$3.41
▼
$13.10
52-Week Range
$2.92
▼
$19.14
Volume
371,678 shs
Average Volume
533,451 shs
Market Capitalization
$451.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

NGM Biopharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
62.7% Upside
$9.00 Price Target
Short Interest
Bearish
5.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.47 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.11) to ($1.69) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

113th out of 1,023 stocks

Pharmaceutical Preparations Industry

44th out of 501 stocks

See Top Rated MarketRank™ Stocks Here
NGM stock logo

About NGM Biopharmaceuticals (NASDAQ:NGM) Stock

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NGM Stock News Headlines

November 24, 2022 | benzinga.com
NGM Biopharmaceuticals Director Trades $201K In Company Stock
November 24, 2022 | benzinga.com
Director of NGM Biopharmaceuticals Purchased $201K In Stock
November 15, 2022 | finance.yahoo.com
How Much Upside is Left in NGM Biopharmaceuticals (NGM)? Wall Street Analysts Think 462%
November 8, 2022 | finance.yahoo.com
NGM Biopharmaceuticals Third Quarter 2022 Earnings: Beats Expectations
November 7, 2022 | finance.yahoo.com
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
November 4, 2022 | finance.yahoo.com
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
November 4, 2022 | finance.yahoo.com
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
November 4, 2022 | finance.yahoo.com
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
November 4, 2022 | finance.yahoo.com
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
November 3, 2022 | finance.yahoo.com
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
October 31, 2022 | finance.yahoo.com
Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
October 28, 2022 | benzinga.com
Massive Insider Trade At NGM Biopharmaceuticals
October 28, 2022 | benzinga.com
NGM Biopharmaceuticals Director Makes $595K Stock Purchase
October 27, 2022 | finance.yahoo.com
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
October 21, 2022 | finance.yahoo.com
Lead Independent Director David Goeddel Just Bought 68% More Shares In NGM Biopharmaceuticals, Inc. (NASDAQ:NGM)
October 18, 2022 | marketwatch.com
NGM Biopharmaceuticals Shares Rebound From Monday's 52-Week Low, Up 13%
October 18, 2022 | markets.businessinsider.com
Analyst Ratings for NGM Biopharmaceuticals
October 18, 2022 | markets.businessinsider.com
Where NGM Biopharmaceuticals Stands With Analysts
October 18, 2022 | finance.yahoo.com
After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
October 17, 2022 | msn.com
How Is The Market Feeling About NGM Biopharmaceuticals?
October 17, 2022 | markets.businessinsider.com
NGM Bio Plunges As Experimental Drug Fails To Meet Primary Goal In Age-Related Vision Loss Disorder
October 17, 2022 | finance.yahoo.com
NGM's eye drug fails in a Phase 2 clinical trial
October 17, 2022 | marketwatch.com
NGM Biopharmaceuticals Trial for Eye Treatment Misses Primary Endpoint
October 17, 2022 | finance.yahoo.com
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
October 16, 2022 | finance.yahoo.com
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
See More Headlines
Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NGM Company Calendar

Last Earnings
11/03/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NGM
CUSIP
N/A
CIK
1426332
Web
www.ngmbio.com
Phone
(650) 243-5555
Fax
N/A
Employees
225
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+62.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-120,330,000.00
Net Margins
-264.09%
Pretax Margin
-264.09%
Return on Equity
-50.12%
Return on Assets
-42.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.50
Quick Ratio
6.50

Sales & Book Value

Annual Sales
$77.88 million
Price / Sales
5.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.34 per share
Price / Book
1.27

Miscellaneous

Outstanding Shares
81,726,000
Free Float
50,588,000
Market Cap
$451.94 million
Optionable
Optionable
Beta
1.22

Key Executives

  • Mr. William J. Rieflin J.D. (Age 62)
    Exec. Chairman of Directors
  • Dr. David J. Woodhouse Ph.D.Dr. David J. Woodhouse Ph.D. (Age 51)
    CEO & Director
    Comp: $880.75k
  • Ms. Siobhan Nolan Mangini (Age 41)
    Pres, Principal Financial, Accounting Officer & CFO of NGM Biopharmaceuticals
    Comp: $610.75k
  • Dr. Jin-Long Chen Ph.D. (Age 59)
    Founder, Chief Scientific Officer & Director
    Comp: $730.75k
  • Ms. Valerie L. Pierce J.D. (Age 59)
    Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer
    Comp: $582.75k
  • Dr. Hsiao Dee Lieu (Age 52)
    Chief Medical Officer & Sr. VP
    Comp: $625.75k
  • Brian Schoelkopf
    Sr. Director of Corp. Fin. & IR
  • Mr. Brian Muma
    VP of People Operations
  • Dr. Alex DePaoli
    Chief Translational Officer & Sr. VP
  • Jessica Ferreyra Ph.D.
    Chief of Staff, Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NGM Stock - Frequently Asked Questions

Should I buy or sell NGM Biopharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NGM shares.
View NGM analyst ratings or view top-rated stocks.

What is NGM Biopharmaceuticals' stock price forecast for 2023?

7 Wall Street research analysts have issued 12-month price targets for NGM Biopharmaceuticals' shares. Their NGM share price forecasts range from $4.00 to $25.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts price targets for NGM or view top-rated stocks among Wall Street analysts.

How have NGM shares performed in 2022?

NGM Biopharmaceuticals' stock was trading at $17.71 at the beginning of the year. Since then, NGM stock has decreased by 68.8% and is now trading at $5.53.
View the best growth stocks for 2022 here.

When is NGM Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our NGM earnings forecast.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its earnings results on Thursday, November, 3rd. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.02. The firm earned $7.91 million during the quarter, compared to analyst estimates of $7.02 million. NGM Biopharmaceuticals had a negative net margin of 264.09% and a negative trailing twelve-month return on equity of 50.12%.

What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?

3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the NASDAQ under the ticker symbol "NGM."

Who are NGM Biopharmaceuticals' major shareholders?

NGM Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.98%), Vanguard Group Inc. (4.77%), First Light Asset Management LLC (1.17%), Rubric Capital Management LP (1.07%), State Street Corp (1.05%) and Logos Global Management LP (1.04%). Insiders that own company stock include David J Woodhouse, David V Goeddel, Group L P Column, Hsiao D Lieu, Hsiao D Lieu, Jin-Long Chen and Peter Svennilson.
View institutional ownership trends.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $5.53.

How much money does NGM Biopharmaceuticals make?

NGM Biopharmaceuticals (NASDAQ:NGM) has a market capitalization of $451.94 million and generates $77.88 million in revenue each year. The company earns $-120,330,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis.

How many employees does NGM Biopharmaceuticals have?

The company employs 225 workers across the globe.

How can I contact NGM Biopharmaceuticals?

NGM Biopharmaceuticals' mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ngmbio.com. The company can be reached via phone at (650) 243-5555 or via email at ir@ngmbio.com.

This page (NASDAQ:NGM) was last updated on 12/6/2022 by MarketBeat.com Staff